The bone morphogenetic protein 6 (BMP6) antibody is a key tool for studying BMP6. a member of the TGF-β superfamily involved in regulating bone formation, iron homeostasis, and cellular differentiation. BMP6 binds to type I/II serine/threonine kinase receptors, activating SMAD1/5/8 signaling pathways to modulate gene expression. Researchers use BMP6 antibodies in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to detect protein expression, localization, and quantification in tissues or cell lines. These antibodies are critical for investigating BMP6's role in diseases such as iron overload disorders (e.g., hemochromatosis), skeletal abnormalities, and cancers, where dysregulated BMP6 signaling is implicated. Specificity is validated via knockout controls or blocking peptides to ensure accurate detection. Commercial BMP6 antibodies are available as monoclonal or polyclonal forms, often targeting epitopes within conserved regions. Recent studies highlight BMP6's therapeutic potential, such as in treating anemia or osteoporosis, driving demand for high-affinity antibodies. However, variability in antibody performance across experimental conditions requires careful optimization. Overall, BMP6 antibodies remain indispensable for elucidating the protein's biological functions and translational applications.